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lnterleukin-4 (IL-4) represents a prototypic lymphokine 
(for a recent review see Paul, 1991). It promotes 
differentiation of B-<:ells and the proliferation of T- and 
B-<:ell, and other cell types of the lymphoid system. An 
antagonist of human IL-4 was discovered during the 
studies presented here after Tyr124 of the recombinant 
proteinbad been substituted by an aspartic acid residue. 
This IL-4 variant, Y124D, bound with high affinity to 
the IL-4 receptor (K0 = 310 pM), but retained no 
detectable proliferative activity for T -<:ells and inhibited 
IL-4-dependent T -cell proliferation competitively 
(Ki = 620 pM). The loss of efficacy in variant Y124D 
was estimated to be > 100-fold on the basis of a weak 
partial agonist activity for the very sensitive induction 
of CD23 positive B-<:ells. The subsitution of Tyr124 by 
either phenylalanine, histidine, asparagine, Iysine or 
glycine resulted in partial agonist variants with unaltered 
receptor binding atTmity and relatively small deficiencies 
in efficacy. These results demoostrate that high affinity 
binding and signal generation can be uncoupled efticiently 
in a Iigand of a receptor betonging to the recently 
identified hematopoietin receptor family. In addition we 
show for the fli"St time, that a powerful antagonist acting 
on the IL-4 receptor system can be derived from the IL-4 
protein. 
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lntroduction 
Interleukin-4 (IL-4) represents a typical immunoregulatory 
lymphokine (for review see Paul and Ohara, 1987; 
Finkelman et a/., 1990; Paul, 1991). lt is produced mainly 
by activated T -cells and mast cells and has a wide range of 
biological activities on various cell types of the lymphoid 
system. B-cells are stimulated in vitro to express dass II 
major histocompatibility complex (MHC II) molecules, the 
IgE low affinity receptor (FcERII, CD23) and immuno-
globulins dass E and G 1. DNA synthesis is induced in 
activated B-cells, as weil as in mature T -cells, foetal 
thymocytes, mast cells and others. 
Mice treated with neutralizing antibodies directed against 
IL-4 or against the IL-4 receptor (Finkelman et al. , 1990; 
Urban,Jr et al., 1991), as well as mice bearing an inactivated 
IL-4 gene (Kühn et al. , 1991), are unable to produce lgE 
and show reduced serum Ievels of IgG 1 after challenge with 
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the relevant stimuli. This indicates a physiological role of 
IL-4 at least in the regulation of lgE Ievels, most likely by 
acting as an isotype switching factor. Consequently, IL-4 
may exert a pathophysiological role in the generation of 
disease states, as for example hyper-lgE syndrome or IgE-
mediated allergic conditions (see Finkelman et al., 1990; 
Tepper et al., 1990). 
IL-4 function is mediated by its binding to plasma 
membrane receptors occurring at the relatively small 
numbers of 150-2500 molecules per target cell (Cabrillat 
et al. , 1987; Park et al. , 1987). A single dissociation 
constant of - 100 pM has been determined for this inter-
action. The IL-4 receptor probab1y comprises only a single 
polypeptide chain of - 800 amino acid residues as suggested 
by chemical crosslinking experiments using 1251 Iabelied 
IL-4 (Mos1ey et al. , 1989; Galizzi et al. , 1990; Harada 
et al., 1990; ldzerda et al., 1990). Binding to IL-4 in vitro 
is not influenced by structural elements apart from the 
extracellular portion of the receptor, since similar 
dissociation constants were found for association with IL-4 
with the entire receptor and only the Iigand binding domain 
in the case of both the mouse and the human protein 
(Maliszewski et al. , 1990; Garrone er al. , 1991). At pre-
sent it is unclear if a second protein aggregates with the 
receptor after IL-4-induced activation. The IL-4 receptor is 
evolutionarily related to the large family of hematopoietin 
receptors, induding receptors (or receptor subunits) for 
interleukins-2, 3, 4, 5, 6 and 7, for GM- and G-CSF and 
also for erythropoietin, growth hormone and prolactine 
(Bazan, 1990a,b; Cosman et al., 1990). Allthese proteins 
show particular homologies in the amino acid sequence of 
their extracellular Iigand binding domains. 
NMR studies revealed a three-dimensional structure of 
human IL-4 comprising a four-helix bundle motif with an 
up-up-down-down connectivity (Redfield et a/. , 1991) 
similar to both human and porcine growth hormone (Abdel-
Meguid er a/. , 1987; De Vos et al. , 1992). Other ligands 
binding to members of the haematopoietin receptor family 
also appear tobe helically organized proteins (see Bazan, 
1990a,b). The crystal structure ofhuman IL-2 shows a four-
helix bundle (Brandhuber et al. , 1987) albeit with a 
connectivity different from IL-4. The amino acid sequences 
of these ligands display no clear homo1ogies. A puzzling 
similarity, however, is apparent in the pattem of amino acid 
residues forming one surface of a putative amphipathic helix 
at the C-terminus ofthese proteins (Sanderson er al., 1988; 
see Bazan, 1990b). Sequence positions involved in receptor 
binding have been identified in several 1igands of the 
haematopoietin receptor family, e.g. in IL-2 (Collins et al., 
1988; Weige1 et al., 1989; Zurawski and Zurawski, 
1989), growth hormone (Cunningham and WeHs, 1991; 
Cunningham et al., 1991), GM-CSF and IL-5 (Shanafelt 
et al., 1991). Amino acid residues involved in signal 
generation, however, have been more difficu1t to identify. 
In order to address this issue, contributions of particular 
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amino acids to receptor affinity and biological activity, 
respectively, have to be distinguishable. As yet, uncoupling 
of receptor binding from biological effects has been observed 
to some extent only in the case of certain mutant derivatives 
of both human and murine IL-2 (Liang et al., 1988; 
Zurawski et al. , 1990). 
Recently we have generated a set of mutant variants of 
human IL-4 with single substitutions at the positions of all 
cysteinyl and aromatic residues (Kruse et al., 1991). One 
of these variants, Y124D, was completely inactive even at 
micromolar concentrations during a T-cell proliferation 
assay. Subsequently, we realized that variant Y124D 
efficiently inhibits IL-4 induced T -cell proliferation. This 
promoted the generation of IL-4 variants in which Tyr124 
was substituted by residues differing in size, polarity or 
charge, respectively. The receptor binding affinity of these 
isolated mutant proteins was determined, as weil as their 
biological activities in two in vitro assays differing in 
sensitivity by nearly two orders of magnitude. The results 
of these experiments indicated that the nature of the side 
chain at position 124 of human IL-4 dramatically affects 
signal generation and biological activity, while the influence 
on receptor binding is marginal. 
The demonstration of the feasibility to obtain an efficient 
antagonist of the IL-4 receptor system has several important 
implications. First, inhibitory IL-4 variants represent 
potential drugs helpful for example in the treatment of lgE-
mediated diseases (see e.g. Pinkelman et al., 1990; Paul, 
1991) similar to therapeutic monoclonal antibodies against 
IL-4 or to the soluble extracellular IL-4 receptor domain 
(Maliszewski et al. , 1990; Garrone et al. , 1991). Secondly, 
antagonistic ligands may prove valuable tools for the 
investigation of IL-4 receptor-mediated signal transducing 
mechanisms. Thirdly, considering the homologies and 
similarities mentioned above, it is an intriguing possibility 
that similar antagonistic variants will be found for other 
ligands of this receptor family (see also Zurawski et al., 
1990). 
Results 
Reduced efficacy of IL4 variants in T -cell proliferation 
Recombinant human IL-4 promoted DNA synthesis in 
prestimulated T -cells with a half-maximal response at a 
concentration (EC50) of 230 pM (Figure 1). Substitution of 
Tyr124 by aspartic acid near the C-terminus of the 
129-residue D-4 resulted in the mutant protein Y124D, which 
bad no measurable activity in the T -cell proliferation assay 
(see also Kuruse et al., 1991). Substitution of Tyr124 by 
a series of other amino acid residues caused less pronounced 
alterations. As the mutant protein Y124F bad the same 
bioactivity as wild type IL-4 (see Table I for statistical 
evaluations), the hydroxyl group ofTyr124 is not essential. 
His124 caused a small but significant reduction of the 
maximal response. Asparagine, Iysine or glycine at this 
position reduced the potency to 29-13% ofwild type IL-4. 
A comparison ofmutant proteins Y124N and Y124D clearly 
demonstrated that the introduction of a negative charge 
caused the most dramatic effect on IL-4 activity. 
Remarkably, the half-maximal response of the residual 
activity (EC50) of the mutant proteins remained within the 
same concentration range ( 130-230 pM) as found for wild 
type IL-4. This is a typical characteristic of partial agonists 
for which binding and signal generation (efficacy) are 
3238 
Q) 100 • IL-4 Cl) 
c: 
c: 8. 80 Cl) 0 ! ii a; i E 60 
e -~ 40 Q. E 
"i 0 
:! 'E 20 ~ 
~ 0 
10 100 1000 
IL-4 or mutant protein (pM) 
Fig. 1. Proliferation of prestimulated T -cells (PHA blasts) in response 
to increasing concentrations of IL-4 <•> and mutant proteins Yl24F 
(0), Yl24H (~). Yl24N ('V), Yl24K (A), Yl24G (6) and 
Yl24D (e). 
partially uncoupled (Ruffolo,Jr, 1982; Black, 1989). The 
unaltered EC50 values for the variants further suggest that 
the response is limited by receptor occupancy (Ruffolo,Jr, 
1982). Mutantproteins affected in receptor binding (see e.g. 
Collins et al., 1988; Weigel et al., 1989; Zurawski and 
Zurawski, 1989; Cunningham and Wells, 1991; 
Cunningham et al. , 1991; Shanafelt et al. , 1991) show a 
different behaviour such that they produce a maximal 
response similar to the wild type if applied in sufficient 
concentrations. 
Partial agonism of IL-4 variants in B-eeil differentiation 
Compared with the T -cell proliferation assay, much lower 
concentrations of IL-4 were sufficient to stimulate B-cells 
for the induction of CD23 (FceRII), the low affinity IgE 
receptor (Kikutani et al., 1986; DeFrance et al., 1987). 
After stimulation, the number of CD23 positive cells 
increased with EC50 of -0.4 pM for IL-4 (Figure 2A) (see 
also Solari et al., 1989). In this very sensitive assay, mutant 
protein Y124D behaved as a partial agonist. The number 
of B-cells that were stimulated by Y124D to express CD23 
was up to 45% ofthat found for wild type IL-4, with an 
EC50 of 210 pM. Very high IL-4 concentrations did not 
increase the number of CD23 positive cells further, but 
stimulated higher mean CD23 expression in the responding 
cells as also determined by FACS analysis. The mean EC50 
was 5 pM IL-4 in different experiments (see Table 1). Mutant 
protein Y124D induced a maximal response of8% compared 
with wild type IL-4 (Figure 2B). Half-maximal response 
occurred at 310 pM Yl24D. These results clearly established 
that the mutant protein Y124D has a very weak partial 
agonist activity that was detectable only in the sensitive B-
eeil assay. The effective concentration for the half-maximal 
response of 210 pM and 310 pM, however, was in the range 
of the EC50 found for IL-4 and the other mutant proteins 
in the T -cell system. 
Variant Y 1240 induced a maximal number of CD23 
positive B-cells (99%) and a maximal mean CD23 content 
(77%) similar to IL-4 ( = 100%). The EC50 for these 
responses, however, were found tobe increased several-fold 
to -5 and 40 pM, respectively (Figures 2A and B, seealso 
Table 1). Seemingly, these are the properties of a variant 
defective in receptor binding. However, Y124G shows 
normal receptor affinity during competitive radioligand 
binding to B-lymphoma cells and normal EC50 during the 
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Table I. Effective concentration (EC5o) and maximal response (Rmax> of IL-4 and 11-4 variants evaluated from T- and B-eeil assays 
Protein T -cell eroliferation B-eeil (seleen) 
EC50 (pM) Rmax (%) Mean C023 content Number of C023 ~sitive cells 
EC50 (pM) Rmax (%) EC50 (pM) Rmax (%) 
IL-4 230 (140-390) 100 ± 7 5 (2.5- 10) 100 ± II 0.4 (0.1-1.6) 100 ± 6 
Variant YI24F 150 (I 10-210) 97 ±6 
Variant Y 124H 190 (130-290) 82 ± 5 
Variant YI24N 220 (170-290) 29 ± 7 
Variant Y124K 230 (2 10-250) 20 ±4 
Variant Y 124G 130 (120-140) 13 ± 4 -40 -77 -5 -99 
Variant Y1240 <0.5 ± 0.7 310 (160-620) 8 ± 3 -210 (120-360) 45 ± 6 
EC50 values were distributed log normal. Numbers in brackets were ca1culated from log EC50 ± log SO. 
Rmax values ± SO were related to Rmax of IL-4 as 100%. 
Approximate va1ues (-) were obtained from a single experiment. 
T -cell proliferation assay (see Tables I and II). Thus, the 
properties of partial agonist Y l24G are consistent with an 
IL-4 receptor system in B-cells operating at low occupancy 
during CD23 induction. In this case, the EC50 values for 
a partial agonist are expected to increase proportionally to 
the loss of efficacy (Ruffolo,Jr, 1982). 
The CD23 positive cells represented 67% of the total cells 
analysed by FACS. This percentage remained constant at 
all saturation Ievels. Thus, the induction of the number of 
CD23 positive cells and the induction of mean CD23 content 
most probably reflected two aspects of the same process in 
the same ceil population. Of two alternatives-either each 
induced cell immediately develops a fuil CD23 content or 
the whole population is first induced to develop a low CD23 
content which upon higher stimulation is increased-the 
second is consistent with the observed data. 
Competitive receptor binding 
The dose-response curves suggest that the amino acid 
exchanges at position 124 did not dramatically alter the 
receptor affinity of the mutant proteins compared with wild 
type IL-4. This has been corroborated by radioligand 
receptor binding experirnents (Figure 3). IL-4, as weil as 
the mutant proteins studied here, competed efficiently with 
iodinated IL-4 for the IL-4 receptors present on the B-
lymphoma ceilline Raji (Cabrillat et al., 1987; Parket al., 
1987) as shown in Figure 3 for Y124G and Y124D. The 
displacement curves of all variants, with the exception of 
Y124D, were not significantly different from that of IL-4 
(see also Table m. Half-maximal displacement of iodinated 
IL-4 required a 3.4-fold higher concentration of mutant 
protein Y124D compared with that ofiL-4. Corresponding 
competitive binding studies performed with both PHA-
activated T -cells and activated tonsillar 8-cells yielded similar 
relative IC50 values (Table II). (Unfortunately, the large 
numbers of activated B-ceils necessary for radioligand 
binding could not routinely be obtained from human spieen). 
The concentration of 1 nM [ 125I]IL-4 during the 
competitive binding experimentswas -10-fold higher than 
the dissociation constant. Thus, the K0 of the competing 
ligands could not be determined from the IC50 (Munson, 
1983). The K0 of [125I]IL-4 detennined independently (see 
Materialsand methods) was 91 pM for the B-lymphoma cells 
and 81 pM for the PHA-activated T-cells. Assuming a 
receptor dissociation constant K0 of - 100 pM for IL-4 
(see also Cabrillat et al., 1987; Parket al., 1987), mutant 
protein Y124D accordingly bad a K0 of 310 pM. 
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Fig. 2. Induction of the low affinity FeE receptor (CD23) on B-cells in 
response to increasing concentrations of ll..-4 <•> or mutant proteins 
Y124G (~) and Y1240 ( • ). (a) Number of C023 positive B-cells as 
percent of maximal response. (b) Mean C023 content of B-cells. 
Activated human B- and T -cells both expose 500- 1000 
molecules of IL-4 receptor at their surface showing a K0 
of -100 pM in terms ofiL-4 binding (see above). Therefore 
the proliferative response ofT -cells appears to closely follow 
the receptor occupancy. Assuming that in the B-eeil assays 
the biological response is sole1y mediated by the receptor 
with a K0 of 100 pM, the induction of CD23 requires the 
occupancy of only a few percent of the receptors by IL-4. 
We suggest that only in case of the 'emasculated' (Black, 
1989) Y124D mutant protein, the receptor bad to be 
maximally saturated in order to generate a small partial 
response. It remains unclear, however, if the assay periods 
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Table II. Competitive radioligand binding (IC50), receptor dissociation constant (K0 ) and competitive inhibitor constant (Ki) of IL-4 and IL-4 variants 
evaluated from B- and T-cell assays 
Protein PHA-activated T -cells ;::..8-c....:.e.:..:.ll:.::..s__________ T -cell proliferation _8_-c..;....el_l ("_.sp._le_e __ n)'--------
IC50 (%) K0 (pM) Lymphoma (Raji) Tonsillar Ki(pM) mean CD23 number of CD23 
content positive cells 
ICso (%) K0 (pM) IC50 (%) 
IL-4 100 (80-130) 81 ± 7 100 (70-150) 91 ± 5 -100 
Variant Yl24F 75 (70-80) 
Variant Y124H 80 (70-90) 
Variant Y124N 110 (100-120) 
Variant Y124K 110 (100-120) 
Variant Y124G 68 (60-80) 
Variant Y124D 320 (230-450) 340 (280-410) -300 620 (390-990) 810 (620-1050) 1000 (320-3200) 
- 64()'1 - 630" 
IC50 and Ki values were distributed log normal. The IC50 of the variants were related to the IC50 of IL-4 as 100%. Numbers in brackets were 
calculated from log IC50 ± log SD or log Ki ± log SO. 
K0 values ± SD were calculated from Scatchard analyses. 
8Tonsillar B-cells were used in one experiment. 
of several days eonventionally used allow for a straight 
eomparison between receptor occupancy and response. 
Antagonist activity of /L-4 variant Y124D 
The results presented above Iead to the prediction that the 
mutant protein Y124D functions as a pure antagonist in the 
T -cell system and as a partial antagonist of IL-4 in the mueh 
more sensitive B-cell system. This has been actually 
demonstrated by competition experiments (Figure 4). 
IL-4-stimulated proliferation of T -eells was competitively 
inhibited by mutant protein Y124D (Figure 4A). From the 
apparent EC50 in the presenee of different concentrations of 
Y124D an inhibitor constant Ki of 620 pM eould be 
calculated (see Table II). A similar Ki of 810 pM was 
determined during competititon of IL-4-dependent CD23 
induction on B-cells (Figure 4B). lncluded in Table ll is also 
the inhibitory eonstant Ki of 1000 pM for the induction of 
the number of CD23 positive B-cells (Figure 4C). The latter 
value shows a high variability due to the pronounced partial 
agonist aetivity of variant Y124D during this response 
(45%). For the partial agonists Y124G, Y124N, Y124K and 
even for Y124H, and incomplete inhibition of IL-4 aetivity 
was established in the T -cell proliferation assay down to the 
Ievel determined by their respective partial agonist aetivities 
(see Figure 1). The ealeulated Ki values werein the range 
of 200 pM (data not shown). 
A comparison of the dose- response curves in Figure 4A, 
B and C shows that the slopes of the T -cell responses are 
steeper. The same difference was observed for the 
experimental results presented in Figures 1 and 2A, and B. 
The binding curve of [125I]IL-4 to B-lymphoma cells or 
activated T -cells has a slope with a caleulated Hili coefficient 
of 0.81-1.15 (data not shown) similar to the B-eeil 
responses (0.91-1.4). The Hili coeffieient calculated for 
the slope of the dose- response curve for IL-4-dependent 
T -cell proliferation is - 2-fold higher (2 -2. 7). In the 
competitive inhibition experiments, the slope was reduced 
-2-fold in the presence of antagonist Yl24D, bothin the 
T-eell (1.3-1.5) and in the B-eeil (0.5 -0.6) assays. The 
significance of these differenees is still unclear. They might 
also indicate specifie aspeets of receptor activation, but we 
cannot presently rule out an origin from experimental 
eonditions. 
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Fig. 3. Competition for binding to the IL-4 receptor of Raji cells 
between radiolabelled IL-4 and IL-4 <•> or mutant proteins Yl24G 
(b.) or YI24D (e). 
Discussion 
The results presented here indieate conclusively that Tyr 124 
of IL-4 is of crucial irnportance for the poteney of the 
lymphokine for signal generation, but not for the binding 
of IL-4 to its receptor. Whereas biologieal aetivity was 
severely impaired in several substitution mutants at position 
124 (see below), binding of this variant ligands to IL-4 
receptor was not at all or only marginally affected. As 
eompiled in Tables I and ll, this is shown first by radioligand 
reeeptor binding experirnents using the IL-4 receptor of the 
B-lymphoma cell line Raji (Park et al., 1987), or of both 
activated T- and B-cells, secondly, by determining the EC50 
of the partial agonist activities in both the B-eeil and the T-
eell assay and thirdly, by determining the competitive 
inhibitor constants, Ki, in both eellular systerns. 
The impairment of biological activity, i.e. the loss of 
efficacy of IL-4, strongly depends on the nature of the side 
ehain introdueed at position 124. In the T -cell assay, efficaey 
is roouced - 5-fold with side chains of asparagine, Iysine 
and glycine, respectively, and > 1 00-fold with an aspartyl 
side chain (see Table 1). Interestingly, the loss of efficacy 
appears to be less pronouneed during the B-eeil 
differentiation assays. This, however, corresponds to the 
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Fig. 4. Competitive inhibition of IL4-dependent T -cell proliferation. 
(a) IL-4-induced CD23 content of B-cells (b) and IL4-induced number 
of CD23 positive B-cells (c) by mutant protein Yl24D at 
concentrations of 0 nm <•>. 0.67 nM (0), 2 nM (.Ä), and 6.7 nM 
(6). The results in (B) and (C) are corrected by subtracting partial 
agonist activities of variant Yl24D. 
- 40-fold lower EC50 of IL-4 for the mean CD23 induction 
or the 500-fold lower EC50 for induction of CD23 positive 
cells when compared with the T -cell response. 
These apparent discrepancies in IL-4 efficacy can be 
explained in terms of receptor occupancy. The EC50 of 
- 200 pM for T -cell proliferation is similar to the IL-4 
receptor dissociation constant. Accordingly, this response 
may be limited by the number of activated receptors. The 
B-cell response appears to be limited by a signaHing step 
following receptor activation. This step then would determine 
the EC50 of 5 pM (0.4 pM) in these processes, which 
correspond to a receptor occupancy of - 5% (mean CD23 
content) or 0.4% (number of CD23 positive cells). The 
Human IL-4 antagonist mutant proteins 
calculation and its underlying assumptions are detailed in 
Materials and methods. The lower efficacy of the IL-4 
variants can thus be partially compensated for by higher 
receptor saturation. In case of mutant protein Y124D 
maximal response is 8% ( 45%) with an EC50 or 310 pM 
(210 pM) for mean CD23 induction (CD23 positive cells). 
According to these data, the loss of efficacy is 125- to 
300-fold. During the T -cell proliferation assays, the mean 
error of the control was 0.5% of the maximal response of 
IL-4. The responses ofvariant Y124D were within the mean 
error ofthe control. Thus, the efficacy ofY124D is at least 
200-fold lower than that of IL-4 in this system. Although 
these calculations are rough estimates derived from long term 
assays, measuring complex proliferation and differentiation 
processes, at least they should provide information concem-
ing the upper Iimit. (An alternative explanation of the results 
involving a very small subpopulation of receptors, e.g. 
20-50 molecules/cell, with a very low dissociation constant 
in the range of 1 pM in the B-cells appears rather unlikely, 
since the antagonist Y124D inhibits with the sarne inhibitory 
constant of 620-1000 pM both B-and T-cells.) 
The identification of a whole panel of partial agonists 
suggests that the residue at position 124 is directly involved 
in signal generating interactions. The amino acid exchange 
in mutant protein Y124D, however, produces an 
unexpectedly large effect. Thus, additional conformation 
effects appear tobe possible in this case. It may be relevant 
in this respect that variant Y124D does not easily crystallize 
(T.Müller and W.Sebald, unpublished observation) in 
contrast to IL-4 (Cook et al., 1991). It remains to be 
established if further residues in the IL-4 molecule, together 
with Tyr124, form a site distinct from a IL-4 receptor 
binding site, which is involved in signal generation. 
According to the available structural information (Redfield 
et al. , 1991; see also Diederichs et al. , 1991) residues at 
the C-terminal end of helix D are close to Tyr124. Cys127 
forms a disulfide bond to Cys3. Thus, side chains of helix 
A may also be in proximity to Tyr124. It is interesting to 
note that for human GM -CSF, which has the same fold as 
IL-4, a receptor binding site was postulated consisting of 
two peptide stretches centered around Arg24 (helix A) and 
Met79 (helix C) (Diederichs et al. , 1991). According to the 
GM-CSF crystal structure, this binding site would be 
spatially far away from the C-terminus of helix D. 
Tyr124 of human IL-4 is found at the corresponding 
position of murine IL-4 (Sanderson et al., 1988). It occurs 
at the end ofhelix D (Redfield et al., 1991), only six residues 
away from the C-terminus. It has been noted (Bazan, 1990b; 
Sanderson, 1988) that this C-terminal segment has features 
in common with other known ligands of the haematopoietin 
receptor family. Amino acid substitutions of Glu141 of 
murine IL-2 (Zurawski et al., 1990), whose position appears 
tobe equivalent to Tyrl24 of human IL-4, yielded a series 
ofpartial agonists. In particular, murine IL-2 variant Q141D 
was inactive or only weakly active in proliferation assays 
using various celllines. However, high affinity bindingwas 
lost and no competitive inhibition of IL-2-dependent 
proliferation of HT2 cells could be found even at a 
5 x 104-fold molar excess of variant Ql41D. Variant 
Ql41D of murine IL-2 is a capable antagonist, however, 
against mutant proteins of IL-2 with receptor-binding defects. 
miL-2 variants with substitutions of Glu141 by asparagine 
(dass 1), Iysine (dass m. aspartic acid (dass lli) and glycine 
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( class IV), could be grouped into four classes according to 
their differing partial agonist activities. This is unlike the 
variants of human IL-4, where substitutions of Tyr124 by 
asparagine, Iysine and glycine produced very similar agonist 
activities (see Figure 1, Table 1). Thus, it remains unclear 
in how far the generation of partial agonism by an aspartyl 
side chain at the human IL-4 Y124 and at the murine IL-2 
Q141 positions indicates comparable structural requirements. 
Two non-overlapping binding sites were identified in 
human growth hormone (Cunningham and Wells, 1991; 
Cunningham et al., 1991; De Vos et al., 1992) that are 
occupied in a sequential manner by two growth hormone 
receptor molecules. Site 1 comprises the C-terminus of helix 
D (Cunningham et al., 1991). The equivalent ofiL-4 Tyr124 
might be human growth hormone V al185, which is located 
at the end of helix D and which is part of site 1. The 
biological activity of a growth hormone variant V 1850 has 
not yet been assessed. It was postulated (Cunningham et al., 
1991) that non-dimerizing variants of growth hormone, 
which have lost the ability to bind two receptor molecules, 
should show antagonistic properties. 
A natural receptor antagonist was detected in the 
interleukin 1 system. The human protein (IL-1Ra) shares 
19% identical amino acid positions with IL-1 cx and 26% 
identical positions with IL-1ß and is probably composed of 
12 ß-strands. It behaves as a pure antagonist in binding with 
high affinity to the IL-1 receptor (type I) without evoking 
any detectable response (Eisenberg et al. , 1990; Hannum 
et al. , 1990). This indicates that in the IL-1 system receptor 
binding and receptor activation are completely separable. 
An efficient uncoupling of both steps also was obtained by 
single amino acid replacements in IL-1 molecules. IL-1ß 
variants R127G (Gehrke et al., 1990) and D145K (Ju et al., 
1991) as weil as an IL-1 cx variant D 151 Y (Y amayoshi et al. , 
1990) exhibited Iittle biological activity but bound with a 
largely unaltered affinity to the receptor. The discontinuous 
receptor binding site identified in human IL-1ß (Labriola-
Tompkins et al. , 1991) clusters around Arg4 and does not 
comprise the positions determining receptor activation. This 
could argue for a structural separation of two independent 
functional sites in the IL-1 protein. lnterestingly, however, 
significant differences exist among those amino acid residues 
ofiL-1cx, IL-1ß and ll-1Ra that probably provide the contact 
points in each receptor-Iigand complex. Accordingly, an 
apparently unaltered receptor affinity of an engineered 
antagonist might also result from multiple compensating 
effects and it does not necessarily indicate a structural 
independence of the two Iigand domains that bind or activate 
the receptor, respectively. 
Especially for IL-1cx variant D141G pure agonist or partial 
agonist activities were established in various cellular 
responses (Yamayoshi et al., 1990), which resemble our 
results with human IL-4 variant Y124D. Considering the 
fundamental structural differences between IL-1 and IL-4, 
as well as between their respective receptors, it is interesting 
to speculate that the occurrence and the straight forward 
identification of high affinity antagonists in both systems is 
correlated with a single chain composition of both the 
receptors. 
Other more complex receptor systems may put more 
stringent constraints on structural modifications ofthe Iigand. 
In the multichain IL-2 receptor system the intrinsically high 
K 0 of 70 nM of the ß subunit (the homologue of the IL-4 
3242 
receptor) was found to decrease to 5 pM in the presence of 
the cx subunit (see Ringheimet al., 1991). A decreased K0 
of 1.2 nM was observed in YT cells due to the presence 
of a still poorly defined 'Y subunit. Interestingly, IL-2 variants 
affected in cx subunit binding showed an apparently unaltered 
EC50 in the biological assays (Weigel et al., 1989; 
Zurawski and Zurawski, 1989; Ju et al., 1991). For the 
explanation of this puzzling behaviour a model was recently 
proposed (Grant et al., 1992) according to which the cx 
subunit contributes several functions to IL-2-mediated 
signalling through the high affinity IL-2 receptor system. 
Interestingly, the partial agonist and antagonist variants 
affected at position Gln141 ofmurine IL-2 (Zurawski et al., 
1990) were described tobe deficient in 'Y subunit interactions. 
They inhibited efficiently, however, the IL-2 variants 
defective in cx subunit binding. Possibly, the interaction of 
the 'Y subunit and the ß subunit is critical for receptor 
activation and any disturbance of this interaction will reduce 
both receptor binding and receptor activation. This complex 
subunit interplay in the IL-2 receptor system therefore 
complicates its analysis, but may also provide special 
advantages for the engineering of selective agonists (see 
Zurawski, 1991). 
Increasing evidence supports the view that the formation 
of receptor homodimers or the forming of heterooligomers 
represents an important step in receptor transmembrane 
signalling (see Schlessinger, 1988; Williams, 1989; UHrich 
and Schlessinger, 1990). This Ieads to the question how the 
Iigand triggers this aggregation. 'Allosteric receptor 
oligomerization' (Schlessinger, 1988), proposedas a model 
for tyrosine kinase receptors, involves two conformations 
of the extracellular domain. Only the high affinity Iigand 
binding conformation forms oligomers. Bridging of two 
receptor proteins by a single Iigand molecule represents 
another possible mechanism for oligomerization (Ullrich and 
Schlessinger, 1990; Cunningham et al., 1991) supported by 
the recent finding that growth horrnone forms a 1 :2 complex 
with the isolated extracellular receptor domain. For the IL-4 
receptor, no evidence for the occurrence of dimers or 
oligomers has as yet been provided. A single class of IL-4 
receptor or IL-4 binding protein has been identified so far, 
exhibiting one homogeneous dissociation constant of 
- 100 pM. lt remains to be established whether IL-4 
receptor signalling involves the formation of a homodimer 
or whether the aggregation with other hitherto unknown 
proteins is necessary. The availability of antagonist IL-4 
variants will open up new ways to address the question of 
which mechanisms operate during IL-4 receptor signalling. 
Materials and methods 
Production of /L-4 mutsnt proteins 
Human IL-4 and mutant proteins were produced in Escherichia coli, 
subjected to a renaturation step and highly purified by CM-Sepharose 68 
chromatography followed by HPLC (Weigel er al., 1989; Kruse er al., 
1991). By means of in virro mutagenesis Tyrl24 (Kruse er al., 1991) had 
been replaced by phenylalanine, histidine, asparagine, Iysine, glycine or 
aspartic acid, respectively, to generate mutant proteins Yl24F, YI24H, 
YI24N, YI24K, YI24G and YI24D. The mutated genes recloned into the 
expression plasmid were sequenced in both directions (373A DNA 
Sequencer, Applied Biosystems) to confirm the mutation. Protein 
concentration was determined by measuring absorbance at 280 nm. It was 
assumed that I mg IL-4/mJ (50% Acetonitril and 0.1% trifluoracetic acid) 
yields an absorbance of I at 280 nm (E~ilh% = 1). For protein 
measurements of variants deficient in Tryl24, the absorbance at 280 nm 
was multiplied by a factor of 1.15. 
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